Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017;19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.
Art therapy helps trafficking survivors deal with trauma, but anti-trafficking advocates who exhibit survivors’ artwork must guard against re-exploitation.
AMA J Ethics. 2017;19(1):98-106. doi:
10.1001/journalofethics.2017.19.1.imhl1-1701.
Viewing dementia as a distinct disease promotes funding for research but may stigmatize those who have dementia and lead to disinvestment in caregiving.
AMA J Ethics. 2017;19(7):713-719. doi:
10.1001/journalofethics.2017.19.7.mhst1-1707.
Mollie Gordon, MD, Rebecca Chen, MD, John Coverdale, MD, MEd, Mike Schiller, CRMP, Hanni Stoklosa, MD, MPH, and Phuong Nguyen, PhD
Little attention has been given to roles played by human trafficking in health care organizations’ supply chains of key equipment, such as hand sanitizers and gloves.
AMA J Ethics. 2024;26(4):E348-356. doi:
10.1001/amajethics.2024.348.
Dr Hanni Stoklosa and Mike Schiller joins Ethics Talk to discuss their article, coauthored with Drs Mollie Gordon, Rebecca Chen, John Coverdale, and Phuong Nguyen: “How Should Health Care Organizations Limit Roles of Human Trafficking in Their Labor and Supply Chains?”
Hilary Daniel joins Ethics Talk to discuss her article, coauthored with Courtney Perlino and Dr Amy B. Cadwallader: “Which Drugs Should Be on the Essential Medicines List?”
Thomas W. LeBlanc, MD, MA and Amy P. Abernethy, MD, PhD
One strategy to promote adherence is the use of “care pathways,” effectively roadmaps that seek to standardize cancer treatment on the basis of some agreed-upon set of guidelines within a particular center or group of patients.